Five Prime Therapeutics Inc Forecasted to Post Q2 2020 Earnings of ($0.81) Per Share (NASDAQ:FPRX)
Five Prime Therapeutics Inc (NASDAQ:FPRX) – Stock analysts at Jefferies Financial Group issued their Q2 2020 EPS estimates for shares of Five Prime Therapeutics in a research report issued to clients and investors on Wednesday, November 6th. Jefferies Financial Group analyst E. Yang expects that the biotechnology company will post earnings of ($0.81) per share for the quarter. Jefferies Financial Group also issued estimates for Five Prime Therapeutics’ Q3 2020 earnings at ($0.82) EPS.
Several other brokerages also recently commented on FPRX. Zacks Investment Research raised Five Prime Therapeutics from a “sell” rating to a “hold” rating in a report on Tuesday, August 6th. Cowen reaffirmed a “buy” rating on shares of Five Prime Therapeutics in a report on Thursday. ValuEngine raised Five Prime Therapeutics from a “sell” rating to a “hold” rating in a research report on Thursday, August 1st. Finally, Guggenheim lowered Five Prime Therapeutics from a “buy” rating to a “neutral” rating in a research report on Monday, September 30th. One research analyst has rated the stock with a sell rating, five have given a hold rating and two have given a buy rating to the company. The stock currently has a consensus rating of “Hold” and a consensus price target of $14.40.
Five Prime Therapeutics (NASDAQ:FPRX) last announced its earnings results on Wednesday, November 6th. The biotechnology company reported ($1.03) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.95) by ($0.08). The company had revenue of $2.98 million for the quarter, compared to analyst estimates of $4.33 million. Five Prime Therapeutics had a negative return on equity of 62.13% and a negative net margin of 842.84%.
Institutional investors have recently modified their holdings of the stock. Rhumbline Advisers boosted its stake in Five Prime Therapeutics by 8.9% during the 3rd quarter. Rhumbline Advisers now owns 57,190 shares of the biotechnology company’s stock valued at $222,000 after purchasing an additional 4,657 shares during the last quarter. Assenagon Asset Management S.A. boosted its stake in shares of Five Prime Therapeutics by 23.1% in the 3rd quarter. Assenagon Asset Management S.A. now owns 487,857 shares of the biotechnology company’s stock worth $1,890,000 after buying an additional 91,578 shares during the last quarter. Walleye Trading Advisors LLC purchased a new position in shares of Five Prime Therapeutics in the 2nd quarter worth approximately $286,000. Walleye Trading LLC purchased a new position in shares of Five Prime Therapeutics in the 2nd quarter worth approximately $314,000. Finally, Nuveen Asset Management LLC purchased a new position in shares of Five Prime Therapeutics in the 2nd quarter worth approximately $3,128,000. 74.41% of the stock is owned by institutional investors and hedge funds.
In other news, major shareholder Bvf Partners L. P/Il bought 6,833 shares of the firm’s stock in a transaction that occurred on Thursday, October 31st. The stock was acquired at an average cost of $3.85 per share, with a total value of $26,307.05. The purchase was disclosed in a legal filing with the SEC, which is available through this link. Also, major shareholder Bvf Partners L. P/Il bought 525,070 shares of the firm’s stock in a transaction that occurred on Monday, October 7th. The stock was purchased at an average cost of $3.75 per share, with a total value of $1,969,012.50. The disclosure for this purchase can be found here. Over the last three months, insiders bought 2,352,563 shares of company stock valued at $9,131,479. Corporate insiders own 7.10% of the company’s stock.
Five Prime Therapeutics Company Profile
Five Prime Therapeutics, Inc, a clinical-stage biotechnology company, focuses on the discovery and development of innovative protein therapeutics. The company's product candidates comprise Bemarituzumab, an antibody that inhibits fibroblast growth factor receptor 2b, or FGFR2b, which is in Phase III clinical trials to treat patients with gastric or gastroesophageal junction and GEJ cancer; and FPA150, a CD8 T cell checkpoint inhibitor antibody that targets B7-H4 in various cancers, as well as FPT155, a soluble CD80 fusion protein that enhances co-stimulation of T cells through CD28.
See Also: Cash Flow
Receive News & Ratings for Five Prime Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Five Prime Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.